2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krimholtz, M. J. Articles by Viberti, G. Search for Related Content PubMed PubMed Citation Articles by Krimholtz, M. J. Articles by Viberti, G.

Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal Disease

Michael J. Krimholtz^*, Janaka Karalliedde^*, Stephen Thomas^*, Rudy Bilous and Giancarlo Viberti^*

^* Unit for Metabolic Medicine, Department of Diabetes Endocrinology and Internal Medicine, GKT School of Medicine, Kings College London, Guys Hospital, London, United Kingdom; and Department of Diabetes and Endocrinology, James Cook University Hospital, Middlesbrough, United Kingdom

Address correspondence to: Prof. Giancarlo Viberti, Unit for Metabolic Medicine, Department of Diabetes Endocrinology and Internal Medicine, 5th Floor Thomas Guy House, Guy’s Hospital, St. Thomas Street, London SE1 9RT, UK. Phone: +44-2079554826; Fax: +44-2079552985; E-mail: giancarlo.viberti{at}kcl.ac.uk

Combination of an angiotensin-converting enzyme inhibitor (ACEI) with an angiotensin II receptor blocker is advocated as a treatment option in diabetic patients with nephropathy and residual albuminuria while on antihypertensive therapy. Abrogation of albuminuria is a key treatment goal to prevent disease progression. The assumption is that albuminuria reduction is the result of more complete blockade of the renin angiotensin system; thus, the ACEI-angiotensin II receptor blocker combination would have a greater albuminuria-lowering effect than the combination of an ACEI with a calcium channel blocker such as amlodipine, which causes similar reductions in BP but does not affect the renin angiotensin system. Twenty-eight patients who had type 1 diabetes and known diabetic renal disease and had a persistently elevated albumin creatinine ratio (ACR) >10 mg/mmol despite office BP recordings 140/80 mmHg on maximal recommended dose of the ACEI lisinopril were studied. Patients were allocated to receive either candesartan (16 mg/d) or amlodipine (10 mg/d) in addition to preexisting ACEI inhibition and followed for 24 wk in a randomized, double-blind, parallel-group trial. By week 24, ACR fell by 56% with candesartan and 54% with amlodipine (P < 0.01 versus baseline for both) with no significant difference between groups. Mean arterial BP fell between 3 and 6 mmHg similarly in both groups. In neither group was a significant correlation found between the change in ACR and the change in BP. Candesartan and amlodipine lowered ACR and BP by a similar degree. The fall in ACR was disproportionate to the fall of systemic BP and independent of it. The mechanism of the reduction in albuminuria seen with these agents in combination with an ACEI remains to be elucidated.

This article has been cited by other articles:

				S. L. Linas Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(Supplement_1): S17 - S23. [Abstract] [Full Text] [PDF]

				R. Fogari, A. Mugellini, and G. Derosa Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension Journal of Renin-Angiotensin-Aldosterone System, September 1, 2007; 8(3): 139 - 144. [Abstract] [PDF]

				L. M. Russo, E. del Re, D. Brown, and H. Y. Lin Evidence for a Role of Transforming Growth Factor (TGF)-{beta}1 in the Induction of Postglomerular Albuminuria in Diabetic Nephropathy: Amelioration by Soluble TGF-{beta} Type II Receptor Diabetes, February 1, 2007; 56(2): 380 - 388. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673